I
Inhibrx Biosciences, Inc. (INBX)
58.39
0.00 (0.00%)
Get all premium features to the best stock analysis tool
58.39
0.00 (0.00%)
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 3.93 | 6.05 | 10 | |
| Quick ratio | 3.93 | 5.63 | 10 | |
| Debt to Equity | 13.39 | 0.30 | 2.0 | |
| Debt to Assets | 0.73 | 1.04 | 2.0 | |
| Interest coverage | -9.71 | -16.91 | 1.0 | |
| Weighted average score | 5.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 2M | 2M | 200K | 1M | 1M |
| Gross Profit | N/A | 609K | -2M | -1M | -1M |
| Operating Income | -129M | -219M | -331M | -135M | -135M |
| Net Income | -145M | -241M | 1.69B | -140M | -140M |
| EBITDA | -128M | -218M | -329M | -133M | -133M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 57.14 | 5.5 |
| Next quarter | -100 | 27.57 | 5.5 |
| Current year | -100 | 39.6 | 5.5 |
| Next year | N/A | 48.9 | 5.5 |
| Weighted average score | 5.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 6.87 | 7.46 | 10.97 | 6.8 |
| Y/Y | -99.99 | 31.4 | 31.72 | 31.13 | 7.8 |
| 3y average | 147.75 | 208.24 | N/A | -12.01 | 5.5 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 5.3 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $124.2M significantly exceed its total debt $107.0M, ensuring strong financial flexibility
Total current assets $132.8M exceed Total current liabilities $33.8M, highlighting excellent liquidity
Debt-to-equity ratio (13.4) far exceeds the industry average, reflecting over-leverage
Interest coverage ratio (-9.7x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$30.1M limits the company's ability to reinvest or pay down debt